---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-000762"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:51:49.069208+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Aurinia reports preliminary Q4 net revenue $28.4M; LUPKYNIS patients up to 1,525

## Summary
- Preliminary Q4 2022 net revenue ~$28.4M, full-year net revenue ~$134.0M.
- Net product revenue Q4 ~$28.3M, full-year ~$103.5M; 2022 guidance achieved.
- LUPKYNIS patients on therapy at Dec 31, 2022: 1,525, up from 1,354 at Sep 30, 2022.
- Q4 patient start forms ~406, compared to 374 in Q3 2022.
- Reiterates 2023 net product revenue guidance of $120-140M; cash & investments ~$388.7M.

## SEC filing metadata
- accession: 0001628280-23-000762
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828023000762/0001628280-23-000762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828023000762/auph-20230106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-000762
- JSON: https://secwatch.observer/filing/0001628280-23-000762.json
- Plain text: https://secwatch.observer/filing/0001628280-23-000762.txt

## Key facts
- Earnings Releases
  Aurinia Pharmaceuticals Inc. reported fourth quarter and full-year 2022 results: revenue approximately $28.4 million and $134.0 million. Guidance reaffirmed.
  - Period: fourth quarter and full-year 2022
  - Revenue: approximately $28.4 million and $134.0 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Preliminary unaudited net revenue for the fourth quarter and full year 2022 of approximately $28.4 million and $134.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000162828023000762/0001628280-23-000762-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.